CD44 and neoplasm: In Experiment 1, 100 PDAC patient tumor tissues were subjected to the histopathological and IHC analyses of PRX3, phospho-Nrf2 (P-Nrf2 (S40)), CD44 variant 9 (CD44v9), and FOXO3a.